This technology is a murine model of angioimmunoblastic T-cell lymphoma with Rhoa G17V expression, which recapitulates the features of human disease for further study and therapeutic development.
The standard of care treatment for angioimmunoblastic T-cell lymphoma (AITL) is a combination of non-specific chemotherapies, which is associated with side effects and toxicity. As such, there is a need to develop more targeted therapies for the treatment of AITL. However, in order to identify new drug therapies, model systems must be developed that have direct translational potential by recapitulating the genetic landscape, transcriptional profile, and pathological phenotype of the disease.
This technology is a murine model of AITL which harbors mutations commonly associated with angioimmunoblastic T-cell lymphoma, in order to better recapitulate the human disease. In the model, conditional expression of RhoA G17V in T-cells alongside Tet2 knockout mirrors the immunophenotypic and transcriptional features of the human disease. An additional murine lymphoma cell line containing the same mutations has also been identified. These models can be used to and can be used for further study of AITL, as well as in vitro drug screening and in vivo experimentation.
IR CU23322
Licensing Contact: Joan Martinez